Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CD109 Antibodies:
anti-Rat (Rattus) CD109 Antibodies:
anti-Mouse (Murine) CD109 Antibodies:
Go to our pre-filtered search.
Human Monoclonal CD109 Primary Antibody for FACS - ABIN1742450
Probst-Kepper, Geffers, Kröger, Viegas, Erck, Hecht, Lünsdorf, Roubin, Moharregh-Khiabani, Wagner, Ocklenburg, Jeron, Garritsen, Arstila, Kekäläinen, Balling, Hauser, Buer, Weiss: GARP: a key receptor controlling FOXP3 in human regulatory T cells. in Journal of cellular and molecular medicine 2010
Show all 3 Pubmed References
Human Monoclonal CD109 Primary Antibody for IHC (fro), FACS - ABIN2688889
Smith, Hayward, Horsewood, Warkentin, Denomme, Kelton: Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. in Blood 1995
Human Polyclonal CD109 Primary Antibody for IHC, IHC (p) - ABIN4289349
Dong, Lu, Chen, Guo, Liu: CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. in Diagnostic pathology 2015
Human Monoclonal CD109 Primary Antibody for CyTOF, FACS - ABIN4899631
Emori, Tsukahara, Murase, Kano, Murata, Takahashi, Kubo, Asanuma, Yasuda, Kochin, Kaya, Nagoya, Nishio, Iwasaki, Sonoda, Hasegawa, Torigoe, Wada, Yamashita, Sato et al.: High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft ... in PLoS ONE 2013
study showed that stimulated, human B lymphocytes produce active TGF-beta1 from surface GARP/latent TGF-beta1 complexes with isotype switching to IgA production.
GARP (show CNGB1 Antibodies) plays an important role in the pathogenesis of atopic dermatitis.
CD4 (show CD4 Antibodies)(+) CD25 (show IL2RA Antibodies)(+) GARP (show CNGB1 Antibodies)(+) Treg cells are defective in dilated cardiomyopathy patients and GARP (show CNGB1 Antibodies) seems to be a better molecular definition of the regulatory phenotype.
these results define the oncogenic effects of the GARP (show CNGB1 Antibodies)-TGFbeta (show TGFB1 Antibodies) axis in the tumor microenvironment
The CD109 protein was up-regulated in hepatocellular carcinoma tissue compared with adjacent noncancerous tissue. CD109 shRNA knockdown delayed the G1-S phase transition, abrogated cell proliferation, and increased cell apoptosis. Furthermore, CD109 impaired TGF-beta (show TGFB1 Antibodies)/Smad (show SMAD1 Antibodies) signaling through control of p-smad2 (show SMAD2 Antibodies).
CD109 is a putative biomarker for identifying a high-risk group among DLBCL patients.
The most common HPA (show HPSE Antibodies) genotypes among Saudis were HPA-1 (show HPSE Antibodies) a + b- (75%), HPA-2 (show HPSE2 Antibodies) a + b- (62%), HPA-3 a + b- (51.5%), HPA (show HPSE Antibodies)-4 a + b- (99%), HPA-5 (show ITGA2 Antibodies) a + b- (76.5%), HPA (show HPSE Antibodies)-6 a + b- (100%) and HPA (show HPSE Antibodies)-15 a + b + (50%). The prevalent allele among the HPA (show HPSE Antibodies) systems was (a), except in the HPA (show HPSE Antibodies)-15 system where the (b) allele was found in 52% of the subjects.
LRRC32 (show LRRC32 Antibodies) expression is significantly upregulated in human masticatory mucosa during wound healing
Expression levels of CD109 was reduced significantly in psoriasis. Lower expression of CD109 and TGF-beta (show TGFB1 Antibodies) RI was highly correlated with higher expression of Smad7 (show SMAD7 Antibodies) and Ki67 (show MKI67 Antibodies), suggesting that CD109 may induce the pathogenesis of psoriasis through Smad7 (show SMAD7 Antibodies)-mediated degradation of TGF-beta (show TGFB1 Antibodies) RI.
sCD109 can bind TGF-beta (show TGFB1 Antibodies), inhibit TGF-beta (show TGFB1 Antibodies) binding to its receptors and decrease TGF-beta (show TGFB1 Antibodies) signalling and TGF-beta (show TGFB1 Antibodies)-induced cellular responses.
platelet and endothelial GARP (show LRRC32 Antibodies) are not important in hemostasis and thrombosis in mice
Small-scale in vivo screening identified several genes, including Cd109, that encode novel pro-metastatic factors. We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3 (show STAT3 Antibodies) as a critical, pharmacologically targetable effector of CD109-driven lung cancer metastasis
CD109 differentially regulates TGF-beta (show TGFB1 Antibodies)-induced ALK1 (show ACVRL1 Antibodies)-Smad1 (show SMAD1 Antibodies)/5 versus ALK5 (show TGFBR1 Antibodies)-Smad2 (show SMAD2 Antibodies)/3 pathways, leading to decreased extracellular matrix production in the skin; epidermal CD109 expression regulates dermal function through a paracrine mechanism
the GARP (show LRRC32 Antibodies)/LTGF-beta1 complex on Treg cells is a major source of TGF-beta1 (show TGFB1 Antibodies) needed for induction of pTreg cells during the process of oral tolerance.
GP96 (show HSP90B1 Antibodies) serves as an essential chaperone for the cell-surface protein (show CD28 Antibodies) glycoprotein A repetitions predominant (GARP (show LRRC32 Antibodies)), which is a docking receptor for latent membrane-associated TGF-beta (show TGFB1 Antibodies) (mLTGF-beta).
CD109 decreases extracellular matrix production and fibrotic responses during hypoxic wound healing
CD109 is present in serum as a soluble form, and suggest its potential as a novel tumor marker in patients with cancers that express CD109.
CD109 might be an important regulator of osteoclastogenesis.
findings demonstrate that CD109 overexpression in the epidermis reduces inflammation and granulation tissue area and improves collagen organization in vivo.
Induction of both Th17-producing cells and Tregs is caused preferentially by Tregs expressing the latent TGF-beta1 (show TGFB1 Antibodies)/GARP (show LRRC32 Antibodies) complex on their cell surface rather than by secreted latent TGF-beta1 (show TGFB1 Antibodies).
This gene encodes a type I membrane protein which contains 20 leucine-rich repeats. Alterations in the chromosomal region 11q13-11q14 are involved in several pathologies.
150 kDa TGF-beta-1-binding protein
, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7
, CD109 antigen
, Gov platelet alloantigens
, activated T-cell marker CD109
, platelet-specific Gov antigen
, glycoprotein A repetitions predominant
, leucine-rich repeat-containing protein 32
, CD109 molecule
, CD109 antigen-like
, GPI-anchored alpha 2 macroglobulin-related protein
, GPI-anchored alpha-2 macroglobulin-related protein